Accolade (NASDAQ:ACCD) Issues Quarterly Earnings Results

Accolade (NASDAQ:ACCD) issued its quarterly earnings results on Thursday. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.01, Briefing.com reports. Accolade had a negative return on equity of 27.27% and a negative net margin of 31.59%. The firm had revenue of $124.80 million during the quarter, compared to analyst estimates of $123.91 million. During the same quarter in the previous year, the company posted ($0.42) earnings per share. The company’s revenue was up 26.1% compared to the same quarter last year. Accolade updated its FY 2025 guidance to EPS and its Q1 2025 guidance to EPS.

Accolade Stock Down 13.8 %

Shares of ACCD stock traded down $1.27 during midday trading on Friday, reaching $7.92. 688,227 shares of the stock were exchanged, compared to its average volume of 718,072. Accolade has a 1 year low of $6.33 and a 1 year high of $17.00. The company’s 50 day moving average is $9.75 and its two-hundred day moving average is $9.92. The company has a current ratio of 2.35, a quick ratio of 2.35 and a debt-to-equity ratio of 0.48. The firm has a market cap of $613.09 million, a PE ratio of -5.02 and a beta of 2.08.

Wall Street Analyst Weigh In

Several brokerages have issued reports on ACCD. Truist Financial dropped their price target on Accolade from $16.00 to $14.00 and set a “buy” rating for the company in a research note on Friday. Leerink Partnrs reaffirmed an “outperform” rating on shares of Accolade in a research note on Monday, February 26th. Barclays dropped their price target on Accolade from $13.00 to $11.00 and set an “equal weight” rating for the company in a research note on Friday. SVB Leerink started coverage on Accolade in a research note on Monday, February 26th. They issued an “outperform” rating and a $16.00 target price for the company. Finally, Canaccord Genuity Group lowered their target price on Accolade from $18.00 to $16.00 and set a “buy” rating for the company in a research note on Friday. Four equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $14.93.

About Accolade

Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women's health specialists, case management specialists, expert medical opinion providers, and virtual primary care physicians.